Raloxifene (60 mg ver- sus placebo) had no effect on the risk of nonfatal stroke (HR, 1.10; 95% CI, 0.92 1.32) but increased the risk of fatal strokes (HR, 1.49; 95% CI, 1.00 1.24; P=0.05). There has been an increasing recognition that the timing of HT initiation may play a critical role in the overall effect of An analysis of the WHI subjects was performed to test this hypothesis, and interestingly, women <10 years from menopause had no increased risk of coronary heart disease events with any CEE (alone or CEE plus medroxyproges- years post menopause had an elevated risk (HR, 1.28; 95% Table 9. Association Between HT Use and Stroke Risk in Randomized Controlled Trials of Perimenopausal and Postmenopausal Women Trial Total No. Average Age, y HT Regimen Vascular Disease Follow-up Any Stroke, HR mg of MPA (n=1380) vs vs placebo Yes (CVD); nondisabling ischemic stroke or TIA within preceding 90 d (CVD) mg of MPA (n=1380) vs Yes (CAD) 6.8 y (2.7-y unblinded follow- up to HERS) Open HT, 494; open control, 494; blind HT, 404; blind Open HT, 58.6; open control, 58.9; blind HT, 58.5; blind placebo, 59 CEE 0.625 mg/d plus 2.5 mg/d MPA or CEE 0.625 mg/d plus 5 mg/d MPA, if <3 y had passed since menopause at recruitment Randomly allocated (open label, n=1006) to HT (n=502) or no 49.7 Intact uterus: 2 mg of synthetic 17 -estradiol for plus 1 mg of norethisterone acetate for 10 d, and 1 mg of 17 -estradiol for 6 d. Prior hysterectomy: 17 - estradiol 2 mg/d. Enrolled within 24 mo of last menses. 